-
IDWeek Commentary | Dr. Hongzhou Lu: Can ” Online Celebrity Weight Loss Drugs” Also Be Used for HIV-Infected Individuals?
Editor’s Note: “Experiencing weight gain due to medication” is a common concern for many people living with HIV (PLWH). Some antiretroviral therapy (ART) regimens are associated with weight gain and…
-
IDWeek Interview | Dr. Shields: Real-World Study on the Efficacy of Two Generation BL-BLI Combination Therapy for MDR-PA
Editor’s Note: Ceftolozane-tazobactam is a new BL-BLI combination drug, and ceftolozane is a third-generation cephalosporin antibiotic, and tazobactam is a beta-lactamase inhibitor. At the recent 2023 IDWeek in the United…
-
Can MRSA Surveillance Results Be Used to Discontinue Vancomycin for Infections Other Than Pneumonia?
Editor’s Note: At the IDWeek 2023, Dr. Rebekah W. Moehring from the Duke Center for Antimicrobial Stewardship and Infection Control at Duke University presented a fascinating report on the use…
-
IDWEEK Live Interview | Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases
Editor’s Note: Staphylococcus aureus bacteremia is a major cause of bloodstream infections, and hospital-acquired bacterial pneumonia is often caused by multidrug-resistant bacteria. And developing new antibiotics requires patient-centered clinical outcomes.…
-
ESMO Live Update | Dr. Girard Analyzes PAPILLON: Opening New Doors for First-Line Treatment of EGFR Exon 20 Insertion Mutant Advanced NSCLC
Based on the results of the PAPILLON trial, presented at the 2023 ESMO Congress, a dual-specificity EGFR/MET monoclonal antibody has the potential to become a standard of care for EGFR exon 20 insertion mutant advanced or metastatic non-small cell lung cancer (NSCLC), although toxicity management must be approached with caution (Abstract LBA5). Dr. Nicolas Girard,…
-
ASCO China Voice | Professor Wu Yilong Reports Phase III EVEREST Trial Results at ASCO
The American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from June 2 to June 6, 2023. Oncology Insight delves into the forefront of the conference, inviting researchers to share the most prominent Chinese research at ASCO, witnessing the advancement of China’s anti-tumor efforts on the international stage. Professor Wu Yilong from…
-
ESMO 2023 | SKB264 (TROP2-ADC) Shows Promise in the Treatment of HR+/HER2- Metastatic Breast Cancer, Advancing in Multiple Cancer Types
TROP2 (Trophoblast Cell-Surface Antigen 2) is highly expressed in various solid tumors, making it a hot target in the field of oncology. The development of antibody-drug conjugates (ADCs) targeting this antigen has garnered significant attention. At the 2023 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain from October 20th to 24th, an…
-
ESMO Big Shot Interview | pCR reaches 39.8%, short-course radiotherapy followed by cetuximab in combination with CAPOX brings significant benefits to locally advanced rectal cancer patients
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting was held in Madrid, Spain, from October 20th to 24th. Professor Tao Zhang and Professor Kaixiong Tao from Tongji Medical College of Huazhong University of Science and Technology and their team conducted a randomized Phase III trial, the UNION study (Abstract Number: LBA25), entitled “Neoadjuvant…
Connecting Medical Expertise through Media